• Editors
  • Scope
  • Current Issue
  • Archive
  • Instruction for Author
  • Principles and Policies of transparency
  • Policies of corrections and retractions
  • EndNote style


2016 (v.24 no.1)

Translational and Clinical Pharmacology

Korean Society for Clinical Pharmacology and Therapeutics
Quarter
ISSN: 2289-0882

  • Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy

    Kyu-pyo Kim, Hun Jung

    TCP | v.24, no.1, pp.07-12, Mar, 2016

    Abstract

    During the past two years, three immune checkpoint inhibitors, ipilimumab, nivolumab and pembrolizumab, have been approved and revolutionized cancer immunotherapy. Translational andclinical pharmacology of these agents have contributed in identifying patients who will receivebenefit, dose effect relationship and surrogate endpoints of clinical benefit. In addition, populationpharmacokinetics/pharmacodynamics have facilitated scientific clinical development, which has ledto accelerated approval of these agents. This paradigm may show how early phase studies may allowidentification of subgroup of patients who can benefit and subsequent approval of drugs based onsmaller patient population. This may speed the access of effective treatment for patients with lifethreatening diseases.

    Keyword

    immune checkpoint inhibitor, immunotherapy, pharmacokinetics